Radiation oncology firm Accuray is highlighting clinical trial results evaluating once-daily accelerated partial-breast irradiation (APBI) in patients treated with the company's TomoTherapy system.
In a study published in the June issue of Anticancer Research: International Journal of Cancer Research and Treatment, Italian researchers found no recurrence of cancer in the treated breast at median follow-up of 34 months. As well, more than 95% of patients rated the preservation of the normal appearance of the breast as good/excellent (Anticancer Res, June 2016, Vol. 36:6, pp. 3035-3039).
Lead author Dr. Ugo De Paula of San Giovanni-Addolorata Hospital in Rome and colleagues included 111 women treated with APBI following lumpectomy. The group found that delivering the treatment once a day over 10 days had better cosmetic outcomes, lower toxicity, and minimal side effects, Accuray said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
